PETR, J., L. HOGEBOOM, P. NIKULIN, E. WIEGERS, G. SCHROYEN, J. KALLEHAUGE, M. CHMELIK, P. CLEMENT, R. E. NECHIFOR, L. A. FODOR, P. C. D. HAMER, F. BARKHOF, C. PERNET, M. LEQUIN, S. DEPREZ, Radim JANČÁLEK, H. J. M. M. MUTSAERTS, F. B. PIZZINI, K. E. EMBLEM and V. C. KEIL. A systematic review on the use of quantitative imaging to detect cancer therapy adverse effects in normal-appearing brain tissue. MAGMA Magnetic Resonance Materials in Physics, Biology and Medicine. NEW YORK: Springer-Verlag GmbH, 2022, vol. 35, No 1, p. 163-186. ISSN 1352-8661. Available from: https://dx.doi.org/10.1007/s10334-021-00985-2.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name A systematic review on the use of quantitative imaging to detect cancer therapy adverse effects in normal-appearing brain tissue
Authors PETR, J. (276 Germany, guarantor), L. HOGEBOOM (528 Netherlands), P. NIKULIN (276 Germany), E. WIEGERS (528 Netherlands), G. SCHROYEN (56 Belgium), J. KALLEHAUGE (208 Denmark), M. CHMELIK (703 Slovakia), P. CLEMENT (56 Belgium), R. E. NECHIFOR (642 Romania), L. A. FODOR (642 Romania), P. C. D. HAMER (528 Netherlands), F. BARKHOF (528 Netherlands), C. PERNET (208 Denmark), M. LEQUIN (528 Netherlands), S. DEPREZ (56 Belgium), Radim JANČÁLEK (203 Czech Republic, belonging to the institution), H. J. M. M. MUTSAERTS (528 Netherlands), F. B. PIZZINI (380 Italy), K. E. EMBLEM (578 Norway) and V. C. KEIL (528 Netherlands).
Edition MAGMA Magnetic Resonance Materials in Physics, Biology and Medicine, NEW YORK, Springer-Verlag GmbH, 2022, 1352-8661.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30103 Neurosciences
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 2.300
RIV identification code RIV/00216224:14110/22:00125243
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1007/s10334-021-00985-2
UT WoS 000731201900001
Keywords in English Neuroimaging; Radiotherapy; Chemotherapy; Long-term adverse effects; Cognitive decline
Tags 14110131, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Michal Petr, učo 65024. Changed: 31/3/2023 12:19.
Abstract
Cancer therapy for both central nervous system (CNS) and non-CNS tumors has been previously associated with transient and long-term cognitive deterioration, commonly referred to as 'chemo fog'. This therapy-related damage to otherwise normal-appearing brain tissue is reported using post-mortem neuropathological analysis. Although the literature on monitoring therapy effects on structural magnetic resonance imaging (MRI) is well established, such macroscopic structural changes appear relatively late and irreversible. Early quantitative MRI biomarkers of therapy-induced damage would potentially permit taking these treatment side effects into account, paving the way towards a more personalized treatment planning. This systematic review (PROSPERO number 224196) provides an overview of quantitative tomographic imaging methods, potentially identifying the adverse side effects of cancer therapy in normal-appearing brain tissue. Seventy studies were obtained from the MEDLINE and Web of Science databases. Studies reporting changes in normal-appearing brain tissue using MRI, PET, or SPECT quantitative biomarkers, related to radio-, chemo-, immuno-, or hormone therapy for any kind of solid, cystic, or liquid tumor were included. The main findings of the reviewed studies were summarized, providing also the risk of bias of each study assessed using a modified QUADAS-2 tool. For each imaging method, this review provides the methodological background, and the benefits and shortcomings of each method from the imaging perspective. Finally, a set of recommendations is proposed to support future research.
PrintDisplayed: 29/7/2024 05:53